fasudil has been researched along with Chronic Hepatitis C in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, SH | 1 |
| Moon, JS | 1 |
| Pak, BY | 1 |
| Kim, GW | 1 |
| Lee, W | 1 |
| Cho, H | 1 |
| Kim, S | 1 |
| Kim, SJ | 1 |
| Oh, JW | 1 |
1 other study available for fasudil and Chronic Hepatitis C
| Article | Year |
|---|---|
HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antiviral Agents; Carbamates; Cell Line, Tum | 2018 |